SALT LAKE CITY, May 9, 2023 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it is hosting a booth at Argentum's 2023 Senior Living Executive Conference and Expo, being held May 8-10 in New Orleans, LA.
The conference is the official meeting of Argentum, the leading national association exclusively dedicated to supporting companies operating professionally managed, resident-centered senior living, and is described as an opportunity to connect with thousands of executives and experts in the senior living space, with over 750 exhibiting companies and thousands of participants.
The Company's booth will showcase Co-Diagnostics' upcoming Co-Dx PCR Home™ testing platform and its planned pipeline of respiratory disease diagnostics, including COVID-19, influenza, RSV and tuberculosis.
More information about the conference may be found here. Attendees interested in learning more about the Company and its upcoming Co-Dx PCR Home platform, which is subject to FDA review and is not available for sale, are invited to visit the Company's booth.
About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets state-of-the-art diagnostics technologies. The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR Home™ platform and to locate genetic markers for use in applications other than infectious disease.

| Last Trade: | US$0.36 |
| Daily Change: | 0.007 2.00 |
| Daily Volume: | 1,470,400 |
| Market Cap: | US$21.740M |
November 20, 2025 November 18, 2025 November 13, 2025 November 03, 2025 October 29, 2025 | |

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREEnd of content
No more pages to load